Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries
Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for countries around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614006070/en/
The agreements will provide access to cefiderocol, an antibiotic for the treatment of serious Gram-negative bacterial infections, which may be resistant to other antibiotic treatments. Cefiderocol was recently added to the World Health Organization (WHO) Model List of Essential Medicines and targets a number of Gram-negative WHO priority pathogens. It was approved by the European Medicines Agency in 2020 and, separately, by the U.S. Food and Drug Administration in 2019. Please refer to the detailed indications for cefiderocol found below.
This is the first license agreement for an antibiotic to treat serious bacterial infections between a pharmaceutical company and a non-profit organization driven by public health priorities. Under this agreement, GARDP will manufacture and commercialize cefiderocol through sub-licensees in a large range of countries that have delayed access (if any) to newer antibiotics. The license territory includes all low-income countries, most lower middle- and upper middle-income countries, and select high-income countries (135 countries total, almost 70% of countries worldwide). It includes a significant proportion of the world’s population living in areas most affected by antibiotic resistance.
“Shionogi is proud to work on such an innovative license agreement with GARDP and CHAI to accelerate antibiotic access. Shionogi is committed to ensuring that cefiderocol is accessible worldwide as a potential treatment option for certain highly resistant Gram-negative infections,” stated Takuko Sawada, Director and Executive Vice President, Senior Vice President of Integrated Disease Care Division, Shionogi & Co., Ltd.
“Too often, antibiotic resistance is presented as a problem for the future,” said Manica Balasegaram, Executive Director of GARDP. “In fact, resistant bacterial infections are already costing lives and taking a heavy toll on health systems around the world. We can change that by supporting accelerated access to antibiotics in regions with the highest burden of resistance—that is, where antibiotic access is often neglected, and should be prioritized. Thanks to essential support from our funding partners, and in collaboration with Shionogi and CHAI, GARDP is accelerating global access now, so that doctors and patients who urgently need antibiotics can get them. Antibiotic development and delivery go hand-in-hand in GARDP’s efforts to fight antibiotic resistance.”
Getting cefiderocol to patients in need will require overcoming a number of technical, legal, regulatory and economic barriers. Shionogi and GARDP will collaborate with CHAI, which has expertise working with the public and private sectors to reshape markets and introduce medicines in countries around the world.
“Appropriate diagnosis and treatment of bacterial infections, which would include access to innovative medications like cefiderocol, can improve the treatment of life-threatening infections,” stated David Ripin, Chief Science Officer and Executive Vice President of Infectious Diseases at CHAI. “CHAI is excited to be a part of this partnership that will ensure that this innovative antibiotic is affordable and available to patients when and where they need it.”
The collaboration agreement includes provisions to work with ministries of health and other experts to strengthen hospital-based stewardship programs that ensure appropriate use. These provisions are especially important to avoid fueling resistance to cefiderocol.
According to Kamini Walia, Senior Scientist and Program Officer of AMR at the Indian Council of Medical Research, “New therapeutic options are urgently needed for treating highly resistant infections in Indian patients. Making cefiderocol available to appropriate Indian patients earlier than it was expected to hit Indian markets will be immensely beneficial in treating patients. However, there is need to practice strict stewardship around use of this drug to prevent its misuse and overuse.” India is one of the many countries that may benefit from the license and collaboration agreements.
This project has a broader purpose to pave the way for antibiotic access more generally. Shionogi and GARDP have agreed to publish their innovative license agreement, which may serve as a new baseline for similar agreements in the future. The license and collaboration agreements also offer a dynamic and promising collaborative approach to antibiotic access. By bringing together key actors from the private and non-profit sectors, this project may help overcome barriers so that cefiderocol reaches patients in need.
About the partners
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company has discovered and developed novel medicines for HIV, influenza and antimicrobial resistance and currently markets products in several therapeutic areas including anti-infectives with the first siderophore cephalosporin (cefiderocol). Other therapeutic areas, and the focus of the company’s pipeline, include CNS/psychoneurological diseases, oncology and pain. For more information on Shionogi & Co., Ltd., visit https://www.shionogi.com/global/en/. Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in New Jersey. For more information on Shionogi Inc., please visit https://www.shionogi.com/us/en/. Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu.
The Global Antibiotic Research and Development Partnership (GARDP)
GARDP is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created in 2016 by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. It is developing new treatments to fight drug-resistant infections, with a focus on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children. GARDP is working with over 60 partners in more than 20 countries. Its work is funded by the governments of Australia, Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom and the Canton of Geneva, as well as Médecins Sans Frontières and private foundations. GARDP is registered under the legal name GARDP Foundation. https://gardp.org/
The Clinton Health Access Initiative
The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to saving lives and reducing the burden of disease in low- and middle-income countries. We work with our partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems that can succeed without our assistance. https://www.clintonhealthaccess.org/
GSK collaborated with Shionogi to develop cefiderocol, and both companies are committed to support access to medicines for patients living in low- and middle-income countries (LMICs). To help make cefiderocol affordable and available to more people through the Shionogi collaboration with GARDP and CHAI, GSK will forego its royalties from sales in LMICs.
Ping An Insurance (Group) Company of China, Ltd. is collaborating with Shionogi to develop cefiderocol in Asia through their joint venture companies, and both companies are committed to support access to medicines for patients living in low- and middle-income countries (LMICs). To help make cefiderocol affordable and available to more people in Asia, Ping An Insurance (Group) Company of China, Ltd. supports the Shionogi collaboration with GARDP and CHAI.
Cefiderocol for injection is the first and only siderophore cephalosporin antibiotic for the treatment of serious Gram-negative infections. It has a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore. In addition to entering cells by passive diffusion through porin channels, cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria. These mechanisms allow cefiderocol to achieve high concentrations in the periplasmic space where it can bind to penicillin-binding proteins and inhibit cell wall synthesis in the bacterial cells. Cefiderocol has also demonstrated in vitro activity against certain bacteria that contain problematic resistant enzymes such as ESBLs, AmpC, and serine- and metallo-carbapenemases. Data from multinational surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant A. baumannii complex, P. aeruginosa, Enterobacterales and S. maltophilia. The clinical significance of the in vitro data is unknown. Cefiderocol has no clinically relevant in vitro activity against most Gram-positive bacteria and anaerobic bacteria.
Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Click here for the summary of product characteristics.
Fetroja® (cefiderocol) is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Fetroja is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Senior Worldfirst Executive Joins UK Fintech Storfund29.6.2022 09:00:00 CEST | Press release
After a six month search, Storfund has appointed Worldfirst’s former Global Head of Enterprise, Oliver Whelan, as its Chief Revenue Officer. Whelan, who spent almost a decade at payments fintech Worldfirst, will be responsible for accelerating Storfund’s rapid and profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005094/en/ Oliver Whelan, Chief Revenue Officer (Photo: Business Wire) Available in 20 countries on the world’s biggest marketplaces, including Cdiscount, Back Market, PcComponentes, Fyndiq and Amazon, Storfund is one of the UK’s fastest growing fintechs. But what’s more remarkable in an industry obsessed with scaling loss-making operations, Storfund has achieved this growth whilst turning a profit. The founders took the decision to fund growth from revenue rather than external capital, believing this would create an impact-driven culture: growth would only come if clients saw that its service
Alliance of Tech Founders Line up to Invest in the Next Generation of Global Innovators With $158m Series C Funding Round for Entrepreneur First29.6.2022 08:00:00 CEST | Press release
Entrepreneur First (EF), a scaleup investor in early stage founder talent, has raised a $158m Series C funding round from a group of veteran technology founders, including Patrick and John Collison, Reid Hoffman, Taavet Hinrikus and Matt Mullenweg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005653/en/ Entrepreneur First co-founders Alice Bentinck and Matt Clifford (Photo: Business Wire) Bucking the trend of mounting layoffs and diminishing venture capital volumes across the startup world, owing to fears of a looming recession, the host of successful entrepreneurs and founders are backing EF to unlock opportunities for a diverse set of new global founders. EF’s impressive global roster of backers includes , John and Patrick Collison (co-founders of Stripe), Taavet Hinrikus (co-founder of Wise), Reid Hoffman (co-founder of LinkedIn), Matt Mullenweg (co-founder of Wordpress), Tom Blomfield (co-founder of Monzo and GoC
Mavenir Supports Provision of National Public Warning Systems in Germany and the United Kingdom29.6.2022 08:00:00 CEST | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced it is working closely with four tier one Mobile Network Operators (MNOs) across Germany and the United Kingdom to deliver Cell Broadcast (CB) functionality. CB, a technical specification maintained by 3GPP, is a method of sending messages to multiple mobile telephone users in a defined area at the same time. Mavenir is committed to supporting government agencies and MNOs in delivering high-quality alert and warning systems for use in times of national emergencies, natural disasters such as flash floods, wildfires or earthquakes, terrorist attacks or public unrest. Brandon Larson, Senior Vice President and General Manager of Mavenir’s Multimedia Business Unit said, “The floods experienced in western Germany July 2021, became one of the region's worst natural catastrophes in recent generations. Such unprecedent
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission29.6.2022 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Ipsen is seeking approval of palovarotene, an oral, selective retinoic-acid receptor gamma (RARγ) agonist for the prevention of heterotopic ossification (HO; new bone formation outside of the normal skeletal system). The FDA has assigned 29 December 2022 as the Prescription Drug User Fee Act goal date, which is on track with anticipated regulatory submission timelines. “This FDA submission acceptance marks a significant milestone for those living with FOP in the U.S. where no approved treatment options exist today for this progressive and debilitating ultra-rare genetic disorder,” said Dr. Howard Mayer, Executive Vice President and Head of Research and De
The LYCRA Company Announces New Equity Ownership29.6.2022 01:49:00 CEST | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, today announced that a group of financial institutions, comprising Lindeman Asia, Lindeman Partners Asset Management, Tor Investment Management, and China Everbright Limited (“New Shareholders”), have gained full equity control of the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005988/en/ The LYCRA Company announces new equity ownership. Current management team led by CEO Julien Born continues to run business with full shareholder support. (Photo: Business Wire) The change of equity control follows the conclusion of the receivership process that started in February when the New Shareholders initiated an enforcement action against Ruyi Textile and Fashion International Group Limited, the former parent of The LYCRA Company, for loan defaults associated with its purchase of T